Akebia Therapeutics, Inc. revised earnings guidance for the full year 2022. For the year, the company is increasing its net product revenue guidance for Auryxia to $170 million to $175 million for fiscal year 2022, raising both the top and bottom end of the guidance range by $5 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.4 USD | -6.04% | +11.11% | +12.90% |
04-23 | Averoa Seeks EU Approval for Chronic Kidney Disease Drug | MT |
04-16 | Akebia Therapeutics, Inc. and STA Pharmaceutical Hong Kong Limited Enters into Second Amendment to the Supply Agreement | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.90% | 312M | |
+10.44% | 106B | |
+0.82% | 104B | |
+6.72% | 23.25B | |
-13.89% | 22.5B | |
-6.64% | 18.7B | |
-37.26% | 17.95B | |
-10.98% | 16.99B | |
+8.67% | 14.26B | |
+41.08% | 12.76B |
- Stock Market
- Equities
- AKBA Stock
- News Akebia Therapeutics, Inc.
- Akebia Therapeutics, Inc. Revises Earnings Guidance for the Full Year 2022